NasdaqCM:AKBABiotechs
Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives
Latest FY 2025 Results Set Up Margin Story For Akebia Therapeutics (AKBA)
Akebia Therapeutics (AKBA) closed FY 2025 with Q4 revenue of US$57.6 million and a basic EPS loss of US$0.05, alongside trailing 12 month revenue of US$236.2 million and a trailing basic EPS loss of US$0.02. This puts the focus firmly on how efficiently that revenue is being converted into earnings. The company has seen quarterly revenue move from US$37.4 million in Q3 2024 to a range of US$57.3 million to US$62.5...